Improving vaccines by targeting antigens to dendritic cells.
10.3858/emm.2009.41.2.008
- Author:
Ken SHORTMAN
1
;
Mireille H LAHOUD
;
Irina CAMINSCHI
Author Information
1. The Walter and Eliza Hall Institute of Medical Research, Parkville Victoria 3050, Australia. shortman@wehi.edu.au
- Publication Type:Review
- Keywords:
adjuvants, immunologic;
antibody formation;
CLEC9a protein, human;
DEC-205 receptor;
dendritic cells;
vaccines
- MeSH:
Antibodies, Monoclonal/immunology;
Antibody Formation;
Antigens/*administration & dosage/immunology;
Dendritic Cells/cytology/*immunology;
Humans;
Vaccines/*immunology
- From:Experimental & Molecular Medicine
2009;41(2):61-66
- CountryRepublic of Korea
- Language:English
-
Abstract:
A new approach to enhancing the effectiveness of vaccines is to deliver antigens selectively to dendritic cells (DC) in situ, via monoclonal antibodies specific for particular DC surface molecules. This can markedly enhance CTL responses and, via helper T cells, also enhance antibody responses. DC activation agents or adjuvants must also be administered for effective CTL responses, but in some cases good antibody responses can be obtained without adjuvants. Here we review the role of different DC subsets and different DC target molecules in obtaining enhanced immune responses.
